198 results about "Pharmacological therapy" patented technology

The invention discloses a construction method and application of a multi-scale and multi-level regulation and control network, and relates to the field of biological information.The construction method comprises the following steps that firstly, 20 databases about interaction among protein, transcription factors, enhancer super enhancers, ncRNA and metabolites are collected; 2, performing quality control on each database, and annotating a specific disease physiological state to each regulation and control relationship; 3, integrating molecular regulation and control relationships among different levels according to biological logic; 4, a bidirectional random walk algorithm is adopted to cooperate with a multi-level biological network to predict and mine potential drug treatment targets; the regulation and control network constructed by the method has a multi-level structure and a specific disease physiological state, the dynamic regulation and control network conforming to the real disease physiological state can be constructed, and the method can be applied to mining potential drug targets and exploring pharmacological mechanisms.

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

The invention discloses application of a small-molecule inhibitor of stress particles in preparation of tumor treatment drugs, and relates to the technical field of biological medicines. According to the present invention, the high throughput screening is performed on the 'ChemDiv Protein-Protein Interaction (PPI) Library', such that the small molecule inhibitor of the stress particle, i.e., the compound UA-0007373, is obtained; the research finds that the small-molecule inhibitor can effectively inhibit the formation of cell stress particles caused by G3BP1, so that the drug resistance of tumor cells is reduced. Cell experiments prove that the small-molecule inhibitor can effectively inhibit the formation of stress particles induced by anti-cancer drugs. Therefore, a brand new auxiliary compound is provided for chemical drug treatment of cancers, and a new technical thought can be provided for research and development of cancer drugs.

Disclosed herein are methods of treating a disease selected from graft-versus-host disease (GVHD), systemic sclerosis (scleroderma), chronic lung allograft dysfunction (CLAD), restrictive allograft syndrome (RAS), and bronchiolitis obliterans syndrome (BOS) using a combination of a BTK inhibitor (such as rilzabrutinib) and belumosudil.

The invention discloses a GSH response type cell membrane bionic nano-drug, a preparation method and application, the cell membrane bionic nano-drug comprises cell membrane vesicles serving as a carrier, the cell membrane vesicles are prepared by performing cell membrane extraction and membrane extrusion on immune cells of which the membrane surfaces overexpress azide, and the cell membrane vesicles serve as a carrier. The azide on the cell membrane vesicles and the bio-coupling compound are bonded through a click chemical reaction to form-SH groups, and the-SH groups and the small-molecule inhibitor are combined together in a disulfide bond mode through the cross-linking agent. The drug is connected with a small-molecule inhibitor through a disulfide bond, so that the drug loading rate is relatively higher, the stability is better, and drug leakage in the blood circulation process is relatively less; the small-molecule inhibitor can be completely released only in a tumor site microenvironment, so that the tumor m6A methylation level is reduced, the EMT state is reversed, the tumor drug resistance is overcome, and a better tumor treatment effect is displayed in cooperation with chemotherapy drugs for tumor treatment.

Disclosed herein are methods of using OX40 as a biomarker for predicting clinical sensitivity and therapeutic response of subjects having cancer to treatment with immunotherapeutic agents, and methods of using OX40 as a biomarker for selecting patient population for cancer treatment with immunotherapeutic agents. Disclosed herein are also methods of treating OX40-expressing cancers using immunotherapeutic agents. Further provided herein are kit for predicting the responsiveness of a subject having cancer to treatment with immunotherapeutic agents.

The invention belongs to the technical field of pharmacotherapeutics, and particularly relates to application of theaflavin-3 '-gallate and a medicine prepared from theaflavin-3'-gallate. The theaflavin-3 '-gallate is used as a KEAP1-NRF2 inhibitor and is competitively combined with the KEAP1 to destroy the inhibition effect of the KEAP1 on the NRF2, so that the content of the NRF2 is increased, and the expression of downstream NQO1 and GCLC is improved. Besides, the theaflavin-3 '-gallate protects the liver function by inhibiting the increase of the contents of AST and ALT, and reduces the oxidative stress and lipid accumulation of the liver, so that the theaflavin-3'-gallate has the potential to become a medicine for treating the ethanol-induced liver injury.

A method for treating or alleviating autoimmune encephalitis with an effective amount of a medicament targeting Blys and / or APRIL. Results show that the effective amount of the medicament targeting Blys and / or APRIL exhibits a good safety profile and a relatively good therapeutic effect in the process of treating or alleviating autoimmune encephalitis.

The invention provides an application of a GABA-A receptor negative regulator in preparation of a medicine for treating pan cancer, and belongs to the technical field of medicines. The research finds that in the tumor microenvironment of panthenic cancer, the GABA-A receptor negative regulator acts on the key cancer-promoting gene target of cancer cells for drug therapy, abnormal overexpression of the key cancer-promoting gene causing cancer occurrence and development can be controlled, the inhibition effect of the cancer cells on immune cells is reduced, and the cancer-promoting effect of the cancer cells is improved. The medicine can be used for treating cancer cells, so that an immunosuppressive tumor microenvironment beneficial to cancer cell growth is destroyed, immune infiltration of the cancer tumor microenvironment is readjusted, a normal immune system of an organism is activated to treat the cancer cells, and the medicine can also be used for reducing NF-kb signal channels of the cancer cells to reduce inflammatory factor expression of the cancer cells and promote apoptosis of the cancer cells. The GABA-A receptor negative regulator acts on key cancer promoting gene targets of cancer cells, so that accurate and effective targeted therapy can be carried out on cancers on the molecular level.

Weissella confusa WSG1 with digestion-assisting capacity is provided. The bacterial strain was preserved in the China General Microbiological Culture Collection Center (CGMCC) on Jun. 11, 2021 with a preservation number of CGMCC NO. 22697 and a nucleotide sequence shown in SEQ ID NO: 1. The bacterial strain of the present invention overcomes the problem of poor treatment effect of antibiotics and other medicaments in the prior art, has good safety, can survive in the gastrointestinal environment, has good susceptibility to antibiotics, has a remarkable inhibitory effect on common diarrhea-causing pathogenic bacteria, has digestion-assisting capacity, and is orally administered without toxicity. Therefore, a new available bacterial strain for the development of probiotics for maintaining the health capability of the intestinal tracts of canine organisms is provided herein.

Disclosed is a method for obtaining information on efficacy of chemotherapy for a patient with membranous nephropathy, the method comprising measuring CXCL13 in a biological sample collected from the patient with membranous nephropathy, in which the efficacy of chemotherapy for the patient with use of an anti-CD20 antibody drug is suggested by a measured result.

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

The present disclosure relates to the treatment of cancer with granulocyte-macrophage colony-stimulating factor and checkpoint inhibitor agents.

The invention discloses an agonist of a retinoic acid receptor beta and application of the agonist in preparation of a non-small cell lung cancer medicine in the technical field of biological medicine. The agonist of the retinoic acid receptor beta is saturated odd fatty acid heptadecanoic acid C17: 0; according to the research, the expression of a retinoic acid receptor beta can be up-regulated by adding heptadecanoic acid into the NSCLC cells, so that the sensitivity of the NSCLC cells to retinoic acid treatment is improved. When heptadecanoic acid and retinoic acid are combined for use, the activity and migration ability of NSCLC cells can be further inhibited, and apoptosis of the cells is promoted. The result shows that the heptadecanoic acid plays an important role in controlling the sensitivity of the NSCLC cells to the retinoic acid, the combined use of the heptadecanoic acid and the retinoic acid provides a new drug treatment means for treating the NSCLC, and the heptadecanoic acid and the retinoic acid have potential application value in preparing the drug for treating the non-small cell lung cancer.

The present application relates to a kind of pterostilbene piperidine amide derivatives, its preparation method and medical use, belong to the field of medicinal chemistry and pharmacotherapy.The present application uses pterostilbene as raw material, designs, synthesizes a series of pterostilbene piperidine amide compounds with new structure, and its structure is characterized.The method used in the present application to prepare these compounds has the characteristics of easy-to-get raw material, simple operation and high yield, and can quickly synthesize target compounds.Compared with pterostilbene, the pterostilbene piperidine amide derivatives provided in the present application have significant cell proliferation inhibitory effect on tumor cells.

The invention discloses an antibody specifically binding to CD48-1 protein or an antigen binding fragment thereof and application thereof, and belongs to the technical field of biological medicine. The invention further discloses application of the antigen binding fragment specifically binding to the CD48-1 protein, the antibody, polynucleotide, an expression vector, a host cell and the conjugate. The invention also discloses a pharmaceutical composition which comprises one of the antigen binding fragment specifically binding to the CD48-1 protein, an antibody, polynucleotide, an expression vector, a host cell and a conjugate. The antibody or the antigen binding fragment thereof has the beneficial effects that immunological rejection caused by species difference does not exist, and the antibody or the antigen binding fragment thereof has specific binding performance to human CD48-1 full-length protein, can be used for detecting the CD48-1 protein and diagnosing diseases related to the CD48-1 protein, can be used for preparing drugs specifically binding to the CD48-1 protein, and can be used for preparing the CD48-1 protein. The CD48-1 protein related diseases can be treated or prevented, and the CD48-1 protein has a wide application prospect.

The invention provides a method for regulating and controlling proliferation and movement of human peripheral blood T cells by Amuc1100 protein. The method relates to the technologies of separation, activation and culture of human peripheral blood T cells, CCK-8 cell proliferation detection, Transwell cell chemotactic detection, flow cytometry receptor expression body detection and the like. The application of the Amuc1100 protein to treat T cells proves that the protein can significantly down-regulate the expression of CD25 and CXCR4 of the T cells and inhibit T cell proliferation and CXCL12 induced T cell chemotactic movement respectively. The method and research means for in-vitro regulation of T cell proliferation and chemotactic movement can be applied to targeted regulation of T cells and directional migration of intestinal tracts of the T cells, and are used for maintaining the steady state of the intestinal tracts, relieving intestinal inflammations and screening drugs to treat diseases related to the intestinal inflammations.

The invention relates to medicine, and more particularly to experimental pharmacology, and can be used for creating pharmaceutical compositions and dosage forms for the treatment of traumatic brain injury. For the purpose of broadening the existing range of drugs for the treatment of traumatic brain injury, the use of human apolipoprotein A-I or functionally significant fragments thereof is proposed, wherein the claimed drug contains native apolipoprotein A-I obtained from human blood serum, or recombinant human apolipoprotein A-I, or a functionally significant fragment of human apoA-I. The functionally significant fragment of human apoA-I has a sequence consisting of the amino acid sequence of human apoA-I truncated at the N terminal, and more particularly the amino acid sequence of human apoA-I truncated at the N terminal by 2 amino residues (amino acid residues 3-243). The drug is provided in the form of a pharmaceutical composition containing human apolipoprotein A-I or the functionally significant fragment thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is water for injection or saline solution. A method for treating traumatic brain injury includes locally or parenterally administering said drug to a subject in need thereof in therapeutically effective doses.

The present application provides a new type of drug-infused balloon catheter with controlled drug release, comprising a balloon (1), a catheter (2) and a drug coating (3), the surface of the balloon (1) is coated with a drug coating (3), the drug coating (3) is divided into a first drug coating (31), a second drug coating (32) and a third drug coating (33), the drug release rates of the first drug coating (31), the second drug coating (32) and the third drug coating (33) are different, the drug release cycle is controlled to solve the problem of toxic reactions caused downstream of the blood vessel, and at the same time, the drug release cycle is extended, effectively treating blood vessel laceration caused by excessive expansion, and improving the long-term effect of drug therapy.

The present invention provides an effective pharmacological therapy for pathological repetitive behaviours.

The present application belongs to the field of medicinal chemistry and pharmacotherapy, and particularly relates to a chalcone mannich base compound, a pharmaceutical composition and a preparation method and application thereof. The present application takes paeonol as a raw material, and obtains corresponding 3-substituted and 5-amino-methyl-substituted paeonol mannich base through mannich reaction of paeonol, polyoxymethylene and different organic amines. After the 3-substituted and 5-substituted paeonol mannich base is separated through column chromatography, the chalcone mannich base compound is obtained through Claisen-Schmidt reaction of the 3-substituted and 5-substituted paeonol mannich base and benzaldehyde containing different substituents. Experiments prove that the chalcone mannich base compound improves the physical and chemical properties of the chalcone mannich base and improves the drug efficacy, can solve the problem of poor water solubility, and has good anti-tumor cell proliferation activity.

The invention discloses an active polypeptide for promoting healing of oral ulcer and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the active polypeptide NPTX3 capable of promoting healing of the oral ulcer is DLKPIAEDIPSLEK. An in-vitro experiment result shows that the polypeptide NPTX3 can remarkably promote the scratch closure of the human immortalized keratinocytes at the concentration as low as 500 pM. Transwell migration experiments further prove that the polypeptide NPTX3 can obviously enhance the migration ability of HaCaT cells at the concentrations of 1nM and 10nM, which prompts that the polypeptide NPTX3 may accelerate wound repair by promoting epithelial cell migration. In an SD (Sprague Dawley) rat oral ulcer model, the ulcer healing rate can be obviously improved by locally applying the polypeptide NPTX3 (1 nM, 10 nM). The polypeptide NPTX3 provided by the invention shows excellent activity of promoting cell migration and tissue repair at an extremely low dose, has the advantages of low effective dose, strong biological activity, high safety and the like, and provides an efficient and mild new choice for drug treatment of oral ulcer.

Compositions and methods relating to a pharmacological therapy for a human genetic disease, specifically mitochondrial DNA depletion-deletions syndromes, and more specifically, those related to mutations in the GUK1 gene. The pharmacological therapy involves the administration of deoxyguanosine (dG), a purine nucleoside phosphorylase (PNP) inhibitor, including but not limited to forodesine, or both.

The application discloses a lenvatinib-polyethylene glycol coupling compound and a preparation method and application thereof. The lenvatinib-polyethylene glycol coupling compound has a structure as shown in the formula (I): in the formula (I), n is greater than or equal to 2. The application further provides a nano preparation containing vinpocetine and the lenvatinib-polyethylene glycol coupling compound and used for manufacturing drugs, which can be applied to tumor treatment, effectively improves the limitation of a single drug treatment method on tumor inhibition, and shows a positive application potential in the tumor treatment field.

The invention provides a radiotherapy and chemotherapy drug delivery device, which comprises a main tube body, which is internally provided with a radiotherapy liquid channel and a chemotherapy liquid channel which are not communicated with each other; the radiotherapy assembly comprises a first liquid inlet assembly and a first storage bag, the first liquid inlet assembly is arranged at the first end of the main catheter body and communicated with the radiotherapy liquid channel, and the first storage bag is arranged at the second end of the main catheter body and communicated with the radiotherapy liquid channel; and the chemotherapy assembly comprises a second liquid inlet assembly, the second liquid inlet assembly is arranged at the first end of the main pipe body and communicates with the chemotherapy liquid channel, a first liquid outlet hole communicating with the chemotherapy liquid channel is formed in the second end of the main pipe body, and the first liquid outlet hole is exposed out of the outer side surface of the main pipe body and is staggered from the first storage bag. After the device is placed, accurate and effective radiotherapy and chemotherapy can be carried out at the tumor position, repeated operations are not needed, the risk that brain tissue of a patient is injured and infected is reduced, and the service life of the patient is prolonged.

The present application belongs to the technical field of precision medicine of tumors. Disclosed is the use of a TMED8 gene in the preparation of a drug for treating a tumor and a kit for diagnosing

Provided is a pharmaceutically acceptable formulation comprising a taxane and an acid-activated 2-hydroxypropyl-β-cyclodextrin (CD). Also provided is a method of treating a patient with a taxane. The method comprises infusing the above formulation into the patient. Additionally provided is a method of preparing the above formulation. Further provided is an infusion bag comprising the above formulation.

The invention discloses a blood pathology image analysis system based on artificial intelligence, and relates to the technical field of pathology image analysis, the blood pathology image analysis system comprises a pathology image database module, a sample experiment module, a pathology analysis module, a similar pathology retrieval module, a treatment course segmentation module, a medicine medical analysis module and a stage medical module, the system has the advantages that pathological images can be searched and classified more quickly through the pathological image database module, reference and comparison are provided for analyzing new pathological samples, image information with the highest similarity can be retrieved through the similar pathological retrieval module, and treatment data are extracted to generate treatment course information; the treatment experience of similar cases can be quickly referred, the medicine medical analysis module is beneficial to reasonably selecting medicines and evaluating the medicine treatment effect, the treatment scheme can be dynamically adjusted according to the actual condition of a patient through the stage medical module, the treatment scheme can be adjusted according to different conditions, and the flexibility of the scheme is improved.